Glob­al Blood Ther­a­peu­tics shares spike on buzz about a po­ten­tial No­vo buy­out

Shares of Glob­al Blood Ther­a­peu­tics spiked this morn­ing as Reuters and Bloomberg bat­ted around some new buzz that No­vo Nordisk has been kick­ing the tires, con­sid­er­ing a buy­out.

Reuters re­port­ed that Glob­al Blood Ther­a­peu­tics $GBT has brought in an in­vest­ment banker to ex­plore a pos­si­ble sale, but every­thing is still up in the air.

Cue the in­tense Twit­ter in­ter­est.

Glob­al Blood’s lead ther­a­py is for sick­le cell dis­ease with a big fo­cus on blood dis­or­ders. No­vo, mean­while, has been at work on its he­mo­phil­ia fran­chise, though its biggest ef­forts are for di­a­betes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER